Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Bernick

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Menopause (New York, N.Y.)|February 25, 2022
Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptomsMichael R McClung, Risa Kagan, Shelli Graham, et al.
Menopause (New York, N.Y.)|November 30, 2018
Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptomsJames A Simon, Andrew M Kaunitz, Robin Kroll, et al.
Menopause (New York, N.Y.)|August 22, 2018
WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer historySheryl A Kingsberg, Lisa Larkin, Michael Krychman, et al.
Menopause (New York, N.Y.)|August 26, 2020
Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trialJames H Liu, Denise R Black, Lisa Larkin, et al.
Menopause (New York, N.Y.)|August 3, 2020
17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trialAndrew M Kaunitz, Diana Bitner, Ginger D Constantine, et al.
Pharmacy (Basel, Switzerland)|September 3, 2020
Long-Lasting, Patient-Controlled, Procedure-Free Contraception: A Review of Annovera with a Pharmacist PerspectiveJennifer J Virro, Kathleen Besinque, Christiane E Carney, et al.
Menopause (New York, N.Y.)|March 20, 2019
Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence reviewGinger D Constantine, Shelli Graham, Kate Lapane, et al.
Menopause (New York, N.Y.)|January 3, 2019
Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesteroneSebastian Mirkin, Shelli Graham, Dennis A Revicki, et al.
Menopause (New York, N.Y.)|January 9, 2020
Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)Sebastian Mirkin, Steven R Goldstein, David F Archer, et al.
Journal of Women'S Health (2002)|May 30, 2023
Satisfaction with a Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System Among Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring UsersJeffrey T Jensen, David F Archer, Carolyn L Westhoff, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Menopause (New York, N.Y.)|February 25, 2022
Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptomsMichael R McClung, Risa Kagan, Shelli Graham, et al.
Menopause (New York, N.Y.)|November 30, 2018
Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptomsJames A Simon, Andrew M Kaunitz, Robin Kroll, et al.
Menopause (New York, N.Y.)|August 22, 2018
WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer historySheryl A Kingsberg, Lisa Larkin, Michael Krychman, et al.
Menopause (New York, N.Y.)|August 26, 2020
Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trialJames H Liu, Denise R Black, Lisa Larkin, et al.
Menopause (New York, N.Y.)|August 3, 2020
17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trialAndrew M Kaunitz, Diana Bitner, Ginger D Constantine, et al.
Pharmacy (Basel, Switzerland)|September 3, 2020
Long-Lasting, Patient-Controlled, Procedure-Free Contraception: A Review of Annovera with a Pharmacist PerspectiveJennifer J Virro, Kathleen Besinque, Christiane E Carney, et al.
Menopause (New York, N.Y.)|March 20, 2019
Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence reviewGinger D Constantine, Shelli Graham, Kate Lapane, et al.
Menopause (New York, N.Y.)|January 3, 2019
Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesteroneSebastian Mirkin, Shelli Graham, Dennis A Revicki, et al.
Menopause (New York, N.Y.)|January 9, 2020
Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)Sebastian Mirkin, Steven R Goldstein, David F Archer, et al.
Journal of Women'S Health (2002)|May 30, 2023
Satisfaction with a Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System Among Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring UsersJeffrey T Jensen, David F Archer, Carolyn L Westhoff, et al.
Pageof 4